Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older

  • Read more about Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older

Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study

  • Read more about Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study

COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients

  • Read more about COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients

Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19

  • Read more about Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19

Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study .

  • Read more about Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study .

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

  • Read more about Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19

  • Read more about Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19

Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection

  • Read more about Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection

Clinical Trial of COVID-19 Vaccine(SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine) in Participants Aged 18 Years and Over

  • Read more about Clinical Trial of COVID-19 Vaccine(SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine) in Participants Aged 18 Years and Over

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

  • Read more about A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Current page 210
  • Page 211
  • Page 212
  • Page 213
  • Page 214
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA